标题
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs
作者
关键词
-
出版物
NEUROLOGY
Volume 100, Issue 20, Pages e2114-e2124
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2023-03-28
DOI
10.1212/wnl.0000000000207156
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Quality Reporting of Systematic Review and Meta-Analysis According to PRISMA 2020 Guidelines: Results from Recently Published Papers in the Korean Journal of Radiology
- (2022) Ho Young Park et al. KOREAN JOURNAL OF RADIOLOGY
- Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan
- (2022) Jingqin Luo et al. BRAIN
- If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
- (2022) Christian Haass et al. PLOS BIOLOGY
- Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
- (2022) Michael J. Pontecorvo et al. JAMA Neurology
- Lecanemab in Early Alzheimer’s Disease
- (2022) Christopher H. van Dyck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease
- (2021) Reisa Sperling et al. JAMA Neurology
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J. Page et al. Systematic Reviews
- Brain volume loss due to donanemab
- (2021) Scott Ayton EUROPEAN JOURNAL OF NEUROLOGY
- Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
- (2021) Stephen Salloway et al. JAMA Neurology
- Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
- (2020) Gerald Novak et al. Alzheimers Research & Therapy
- BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
- (2020) Cyrille Sur et al. BRAIN
- Low Evolutionary Selection Pressure in Senescence Does Not Explain the Persistence of Aβ in the Vertebrate Genome
- (2019) Robert D. Moir et al. Frontiers in Aging Neuroscience
- Neuromodulatory action of picomolar extracellular Aβ42 oligomers on pre- and postsynaptic mechanisms underlying synaptic function and memory
- (2019) Walter Gulisano et al. JOURNAL OF NEUROSCIENCE
- Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
- (2019) David Henley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
- (2019) Alette M. Wessels et al. JAMA Neurology
- Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
- (2018) Enchi Liu et al. NEUROLOGY
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
- (2018) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory
- (2017) Agostino Palmeri et al. JOURNAL OF NEUROSCIENCE
- Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase
- (2016) Linfeng Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of -Amyloid Precursor Protein
- (2015) S. Ayton et al. JOURNAL OF NEUROSCIENCE
- Feature Selection with theBorutaPackage
- (2015) Miron B. Kursa et al. Journal of Statistical Software
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
- (2010) J.M. Schott et al. NEUROBIOLOGY OF AGING
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started